US FDA Completes Pre-Approval Inspection at Aurobindo Pharma Subsidiary

$AUROPHARMA Limited has informed the stock exchanges that the US Food and Drug Administration (US FDA) successfully concluded a Pre-Approval Inspection (PAI) at its step-down subsidiary, Eugia Steriles Private Limited, located in Parawada Mandal, Anakapalli District, Andhra Pradesh. The inspection was carried out from June 10 to June 19, 2026, and concluded with five observations. The company stated that it will submit a comprehensive response to the observations within the stipulated timeline. Aurobindo Pharma reaffirmed its commitment to maintaining the highest global quality and manufacturing standards across all its facilities. The company will keep the exchanges updated on any material developments.